Prosthetic Joint Infection Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2026-2036
The global prosthetic joint infection market remains an early-stage therapeutic arena with no prosthetic joint infection-specific drug approvals across major regulators. Current medical management relies on surgery (DAIR, two-stage revision) plus antibiotics; however, these agents are approved for broader infections rather than prosthetic joint infection itself and thus fall outside this scope. Market momentum is driven by rising arthroplasty volumes and a persistent prosthetic joint infection incidence of roughly 1–2% after joint replacement, underscoring a significant unmet need. Emerging pipelines target biofilm-embedded pathogens and staphylococcal dominance with novel mechanisms and regulator incentives.
Impact
The following are the drivers for the global prosthetic joint infection market:
Product/Innovation Strategy: Pinpoint the highest-probability clinical settings (DAIR vs. staged revisions) and refine target product profiles for biofilm eradication, surgical compatibility, and rapid sterilization. Map regulatory advantages (QIDP/Fast Track/Orphan), critical endpoints, and KOL-validated trial designs. Benchmark emerging mechanisms (AMPs, FabI inhibition) to prioritize differentiated assets and inform CMC, delivery, and peri-operative integration strategies.
Competitive Strategy: Compare leading programs on mechanism, spectrum, biofilm activity, phase status, and regulatory incentives. Identify partnership opportunities with orthopedic networks and revision centers to accelerate enrollment and real-world evidence. Build payer narratives around fewer revisions, Length of stay reductions, and functional recovery. Use scenario planning to prepare for first-to-market dynamics and regional access hurdles.
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
Impact
- Increasing demand for prosthetic joint infection therapies is anticipated to support the growth of the global prosthetic joint infection market during the forecast period 2025-2035.
- The global prosthetic joint infection market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing drug approvals for the treatment of prosthetic joint infection.
The following are the drivers for the global prosthetic joint infection market:
- Rising arthroplasty volumes and persistent prosthetic joint infection incidence (?1–2%) expand the eligible population for prosthetic joint infection-specific therapeutics.
- Biofilm-driven treatment failures create demand for novel mechanisms that penetrate biofilms and eradicate staphylococcal burdens.
- Strong U.S. regulatory incentives (QIDP, Fast Track, Orphan) accelerate development timelines and attract capital for antibacterial innovation in prosthetic joint infection.
- Complex trial execution (surgical heterogeneity, microbiology mix, long follow-up) inflates cost and prolongs timelines.
- Endpoint and access uncertainty—payers and HTAs will require robust evidence on revision avoidance, function, and durability to justify adoption.
Product/Innovation Strategy: Pinpoint the highest-probability clinical settings (DAIR vs. staged revisions) and refine target product profiles for biofilm eradication, surgical compatibility, and rapid sterilization. Map regulatory advantages (QIDP/Fast Track/Orphan), critical endpoints, and KOL-validated trial designs. Benchmark emerging mechanisms (AMPs, FabI inhibition) to prioritize differentiated assets and inform CMC, delivery, and peri-operative integration strategies.
Competitive Strategy: Compare leading programs on mechanism, spectrum, biofilm activity, phase status, and regulatory incentives. Identify partnership opportunities with orthopedic networks and revision centers to accelerate enrollment and real-world evidence. Build payer narratives around fewer revisions, Length of stay reductions, and functional recovery. Use scenario planning to prepare for first-to-market dynamics and regional access hurdles.
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
Executive Summary
Scope and Definition
Market/Product Definition
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL PROSTHETIC JOINT INFECTION MARKET: INDUSTRY OUTLOOK
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL PROSTHETIC JOINT INFECTION MARKET, BY REGION, $MILLION, 2025-2036
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Prosthetic Joint Infection Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Prosthetic Joint Infection Market, by Country
2.2.2.1.1 Germany
2.2.2.1.2 U.K.
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of -Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Prosthetic Joint Infection Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-world
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. GLOBAL PROSTHETIC JOINT INFECTION MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations, and Business Expansions
3.2 Company Profiles
3.2.1 Avadel
3.2.1.1 Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers
3.2.1.4 Key Personnel
3.2.1.5 Analyst View
3.2.2 Wellesley Pharmaceuticals, LLC
3.2.2.1 Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers
3.2.2.4 Key Personnel
3.2.2.5 Analyst View
3.2.3 Ferring Pharmaceuticals
3.2.3.1 Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers
3.2.3.4 Key Personnel
3.2.3.5 Analyst View
3.2.4 Idorsia Pharmaceuticals Ltd.
3.2.4.1 Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers
3.2.4.4 Key Personnel
3.2.4.5 Analyst View
3.2.5 Others
4. RESEARCH METHODOLOGY
Scope and Definition
Market/Product Definition
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL PROSTHETIC JOINT INFECTION MARKET: INDUSTRY OUTLOOK
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL PROSTHETIC JOINT INFECTION MARKET, BY REGION, $MILLION, 2025-2036
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Prosthetic Joint Infection Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Prosthetic Joint Infection Market, by Country
2.2.2.1.1 Germany
2.2.2.1.2 U.K.
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of -Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Prosthetic Joint Infection Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-world
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. GLOBAL PROSTHETIC JOINT INFECTION MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations, and Business Expansions
3.2 Company Profiles
3.2.1 Avadel
3.2.1.1 Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers
3.2.1.4 Key Personnel
3.2.1.5 Analyst View
3.2.2 Wellesley Pharmaceuticals, LLC
3.2.2.1 Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers
3.2.2.4 Key Personnel
3.2.2.5 Analyst View
3.2.3 Ferring Pharmaceuticals
3.2.3.1 Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers
3.2.3.4 Key Personnel
3.2.3.5 Analyst View
3.2.4 Idorsia Pharmaceuticals Ltd.
3.2.4.1 Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers
3.2.4.4 Key Personnel
3.2.4.5 Analyst View
3.2.5 Others
4. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Prosthetic Joint Infection Market (by Scenario), $Million, 2025, 2030, and 2036
Figure: Global Prosthetic Joint Infection Market, 2025 and 2036
Figure: Global Prosthetic Joint Infection Market Key Trends, Impact Analysis
Figure: North America Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Europe Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Asia-Pacific Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Rest-of-the-World Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Prosthetic Joint Infection Market (by Scenario), $Million, 2025, 2030, and 2036
Figure: Global Prosthetic Joint Infection Market, 2025 and 2036
Figure: Global Prosthetic Joint Infection Market Key Trends, Impact Analysis
Figure: North America Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Europe Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Asia-Pacific Prosthetic Joint Infection Market, $Million, 2025-2036
Figure: Rest-of-the-World Prosthetic Joint Infection Market, $Million, 2025-2036
LIST OF TABLES
Table: Market Snapshot
Table: Market Dynamics
Table: Global Prosthetic Joint Infection Market (by Region), $Million, 2025-2036
Table: Market Snapshot
Table: Market Dynamics
Table: Global Prosthetic Joint Infection Market (by Region), $Million, 2025-2036
